Current controversies and challenges in allergic rhinitis management

David Price*, Pete Smith, Peter Hellings, Nikos Papadopoulos, Wytske Fokkens, Antonella Muraro, Ruth Murray, Alison Chisholm, Pascal Demoly, Glenis Scadding, Joaquim Mullol, Phil Lieberman, Claus Bachert, Ralph Mösges, Dermot Ryan, Jean Bousquet

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract / Description of output

There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.

Original languageEnglish
Pages (from-to)1205-1217
Number of pages13
JournalExpert Review of Clinical Immunology
Issue number11
Publication statusPublished - 2 Nov 2015

Keywords / Materials (for Non-textual outputs)

  • allergic rhinitis
  • clinical relevance
  • control
  • guidelines
  • randomized controlled trials, real life


Dive into the research topics of 'Current controversies and challenges in allergic rhinitis management'. Together they form a unique fingerprint.

Cite this